Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
- 1 June 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 4 (6), 420-431
- https://doi.org/10.1038/nri1371
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- Adenovirus Vector-Mediatedin VivoGene Transfer of OX40 Ligand to Tumor Cells Enhances Antitumor Immunity of Tumor-Bearing HostsCancer Research, 2004
- The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagementJournal of Leukocyte Biology, 2004
- OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in miceEuropean Journal of Immunology, 2003
- The immunological and genetic basis of inflammatory bowel diseaseNature Reviews Immunology, 2003
- Infliximab in ulcerative colitis: is there a placebo (effect) in the house?Gastroenterology, 2003
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell ClonesJapanese Journal of Cancer Research, 2001
- CD4 T cell traffic control:in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B folliclesEuropean Journal of Immunology, 1999
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- Signals and signs for lymphocyte responsesCell, 1994